411 studies found for:    "Waldenstrom macroglobulinemia"
Show Display Options
Rank Status Study
1 Unknown  Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
Conditions: Waldenström Macroglobulinemia;   Lymphoplasmacytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Drug: Chlorambucil;   Drug: Fludarabine
2 Completed Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
Conditions: Lymphoplasmacytic Lymphoma;   Waldenstrom's Macroglobulinemia
Intervention: Drug: Campath-1H
3 Completed Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia;   Lymphoplasmacytic Lymphoma
Intervention: Drug: Bortezomib (Velcade)
4 Completed
Has Results
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia;   Lymphoplasmacytic Lymphoma
Interventions: Drug: Thalidomide;   Drug: Rituximab
5 Completed Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: BORTEZOMIB
6 Terminated Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Epratuzumab (hLL2- anti-CD22 humanized antibody)
7 Recruiting An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia (WM)
Intervention: Drug: ACP-196
8 Recruiting Ibrutinib With Rituximab in Previously Treated Adults With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
9 Recruiting Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
10 Active, not recruiting Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Conditions: Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-related Toxicity;   Waldenström Macroglobulinemia
Interventions: Drug: temsirolimus;   Biological: rituximab;   Drug: bortezomib;   Drug: dexamethasone;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
11 Terminated Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Biological: ofatumumab;   Drug: bortezomib;   Other: laboratory biomarker analysis
12 Terminated Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Thalidomide;   Drug: Lenalidomide;   Drug: Rituximab
13 Completed Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention: Drug: MLN0128
14 Completed
Has Results
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Perifosine
15 Active, not recruiting Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
16 Completed Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Intervention: Biological: oblimersen sodium
17 Completed Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Thalidomide
18 Active, not recruiting
Has Results
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinaemia
Intervention: Biological: Ofatumumab
19 Completed Sildenafil Citrate in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Sildenafil citrate (Viagra)
20 Terminated
Has Results
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: DT PACE + Rituxan

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years